Quantbot Technologies LP Invests $1.61 Million in Charles River Laboratories International, Inc. (NYSE:CRL)

Quantbot Technologies LP purchased a new stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 8,169 shares of the medical research company's stock, valued at approximately $1,609,000.

Other large investors also recently made changes to their positions in the company. Kayne Anderson Rudnick Investment Management LLC boosted its holdings in Charles River Laboratories International by 1.7% during the second quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,908,989 shares of the medical research company's stock worth $394,359,000 after buying an additional 31,359 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its stake in shares of Charles River Laboratories International by 40.7% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company's stock worth $346,821,000 after acquiring an additional 509,163 shares in the last quarter. Earnest Partners LLC grew its holdings in shares of Charles River Laboratories International by 12.4% in the 2nd quarter. Earnest Partners LLC now owns 1,004,486 shares of the medical research company's stock worth $207,507,000 after acquiring an additional 110,725 shares during the last quarter. Marshall Wace LLP raised its position in shares of Charles River Laboratories International by 24.6% during the second quarter. Marshall Wace LLP now owns 825,905 shares of the medical research company's stock worth $170,615,000 after purchasing an additional 163,056 shares during the period. Finally, Sei Investments Co. lifted its holdings in shares of Charles River Laboratories International by 8.6% during the second quarter. Sei Investments Co. now owns 624,800 shares of the medical research company's stock valued at $129,072,000 after purchasing an additional 49,451 shares during the last quarter. Institutional investors own 98.91% of the company's stock.

Insider Buying and Selling at Charles River Laboratories International

In other news, Director Richard F. Wallman sold 6,621 shares of Charles River Laboratories International stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the sale, the director now directly owns 12,386 shares in the company, valued at approximately $2,676,862.32. The trade was a 34.83 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.30% of the company's stock.

Analyst Ratings Changes

Several research analysts have commented on CRL shares. Baird R W cut shares of Charles River Laboratories International from a "strong-buy" rating to a "hold" rating in a report on Thursday, August 8th. Citigroup lowered Charles River Laboratories International from a "neutral" rating to a "sell" rating and reduced their target price for the company from $215.00 to $175.00 in a report on Tuesday, October 1st. Barclays lowered their price target on Charles River Laboratories International from $230.00 to $210.00 and set an "equal weight" rating on the stock in a report on Thursday, August 8th. StockNews.com downgraded Charles River Laboratories International from a "buy" rating to a "hold" rating in a research note on Thursday, November 7th. Finally, Robert W. Baird lowered their target price on Charles River Laboratories International from $191.00 to $190.00 and set a "neutral" rating on the stock in a research note on Friday, September 20th. Three research analysts have rated the stock with a sell rating, eleven have issued a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $214.38.

Charles River Laboratories International Stock Down 0.3 %

Shares of NYSE:CRL traded down $0.53 on Friday, reaching $199.06. The company had a trading volume of 287,759 shares, compared to its average volume of 621,025. The stock has a 50-day moving average price of $194.32 and a 200 day moving average price of $204.95. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. Charles River Laboratories International, Inc. has a twelve month low of $176.48 and a twelve month high of $275.00. The stock has a market capitalization of $10.18 billion, a P/E ratio of 24.91, a P/E/G ratio of 5.15 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $975.99 million. During the same quarter last year, the firm posted $2.72 EPS. The company's revenue was down 1.6% on a year-over-year basis. On average, equities analysts expect that Charles River Laboratories International, Inc. will post 10.19 EPS for the current year.

Charles River Laboratories International announced that its Board of Directors has approved a stock buyback plan on Wednesday, August 7th that authorizes the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to reacquire up to 9.6% of its shares through open market purchases. Shares repurchase plans are often an indication that the company's board of directors believes its shares are undervalued.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).